BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31606370)

  • 1. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.
    Richman LP; Vonderheide RH; Rech AJ
    Cell Syst; 2019 Oct; 9(4):375-382.e4. PubMed ID: 31606370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
    Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
    Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
    Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
    Su S; Chen F; Xu M; Liu B; Wang L
    Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification.
    Tang Y; Wang Y; Wang J; Li M; Peng L; Wei G; Zhang Y; Li J; Gao Z
    BMC Bioinformatics; 2020 Nov; 21(1):532. PubMed ID: 33208106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
    Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
    Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
    Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
    Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoantigens in response to immune checkpoint blockade.
    Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
    Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens.
    Grimaldi A; Cammarata I; Martire C; Focaccetti C; Piconese S; Buccilli M; Mancone C; Buzzacchino F; Berrios JRG; D'Alessandris N; Tomao S; Giangaspero F; Paroli M; Caccavale R; Spinelli GP; Girelli G; Peruzzi G; Nisticò P; Spada S; Panetta M; Letizia Cecere F; Visca P; Facciolo F; Longo F; Barnaba V
    Commun Biol; 2020 Feb; 3(1):85. PubMed ID: 32099064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
    Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
    Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
    Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy.
    Sng CCT; Kallor AA; Simpson BS; Bedran G; Alfaro J; Litchfield K
    Front Immunol; 2024; 15():1347542. PubMed ID: 38558815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.